PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
34937801-1	2022	Idasanutlin is a potent inhibitor of the p53-MDM2 interaction that enables re-activation of the p53 pathway which induces cell cycle arrest and/or apoptosis in tumor cells expressing functional p53.	RG7388	0-11	tumor protein p53	Homo sapiens	41-44
34933330-0	2022	MDM2 antagonist idasanutlin in patients with polycythemia vera: results from a single-arm phase 2 study.	RG7388	16-27	MDM2 proto-oncogene	Homo sapiens	0-4
34933330-1	2022	Idasanutlin, an MDM2 antagonist, showed clinical activity and rapid reduction in JAK2 V617F allele burden in patients with polycythemia vera (PV) in a phase 1 study.	RG7388	0-11	MDM2 proto-oncogene	Homo sapiens	16-20
34933330-1	2022	Idasanutlin, an MDM2 antagonist, showed clinical activity and rapid reduction in JAK2 V617F allele burden in patients with polycythemia vera (PV) in a phase 1 study.	RG7388	0-11	Janus kinase 2	Homo sapiens	81-85
34933330-12	2022	Overall, the idasanutlin dosing regimen showed clinical activity and rapidly reduced JAK2 allele burden in patients with HU-resistant/intolerant PV but was associated with low-grade gastrointestinal toxicity, leading to poor long-term tolerability.	RG7388	13-24	Janus kinase 2	Homo sapiens	85-89
34937801-1	2022	Idasanutlin is a potent inhibitor of the p53-MDM2 interaction that enables re-activation of the p53 pathway which induces cell cycle arrest and/or apoptosis in tumor cells expressing functional p53.	RG7388	0-11	MDM2 proto-oncogene	Homo sapiens	45-49
34465864-7	2022	Furthermore, combination therapy with a JAK3 inhibitor (tofacitinib) and a MDM2 inhibitor (idasanutlin) reduces the Phf6 KO and JAK3M511I leukemia burden in vivo.	RG7388	91-102	Janus kinase 3	Mus musculus	40-44
34937801-1	2022	Idasanutlin is a potent inhibitor of the p53-MDM2 interaction that enables re-activation of the p53 pathway which induces cell cycle arrest and/or apoptosis in tumor cells expressing functional p53.	RG7388	0-11	tumor protein p53	Homo sapiens	96-99
34465864-7	2022	Furthermore, combination therapy with a JAK3 inhibitor (tofacitinib) and a MDM2 inhibitor (idasanutlin) reduces the Phf6 KO and JAK3M511I leukemia burden in vivo.	RG7388	91-102	transformed mouse 3T3 cell double minute 2	Mus musculus	75-79
34937801-1	2022	Idasanutlin is a potent inhibitor of the p53-MDM2 interaction that enables re-activation of the p53 pathway which induces cell cycle arrest and/or apoptosis in tumor cells expressing functional p53.	RG7388	0-11	tumor protein p53	Homo sapiens	194-197
34465864-7	2022	Furthermore, combination therapy with a JAK3 inhibitor (tofacitinib) and a MDM2 inhibitor (idasanutlin) reduces the Phf6 KO and JAK3M511I leukemia burden in vivo.	RG7388	91-102	Janus kinase 3	Mus musculus	128-132
34937801-5	2022	Idasanutlin"s clearance is dependent on CYP3A4/2C8, forming its major circulating metabolite M4, with contributions from UGT1A3 and biliary excretion.	RG7388	0-11	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	40-50
34937801-5	2022	Idasanutlin"s clearance is dependent on CYP3A4/2C8, forming its major circulating metabolite M4, with contributions from UGT1A3 and biliary excretion.	RG7388	0-11	UDP glucuronosyltransferase family 1 member A3	Homo sapiens	121-127
34937801-6	2022	Idasanutlin and M4 have low permeability, very low clearance and extremely low unbound fraction in plasma (<0.001) which makes in vitro data showing inhibition on CYP3A4/2C8 enzymes challenging to translate to clinical relevance.	RG7388	0-11	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	163-173
34937801-9	2022	Co-administered strong CYP3A and CYP2C8 inhibitors might lead to weak or moderate idasanutlin exposure increases and the strong inducer rifampicin might cause moderate exposure reduction.	RG7388	82-93	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	23-28
34937801-9	2022	Co-administered strong CYP3A and CYP2C8 inhibitors might lead to weak or moderate idasanutlin exposure increases and the strong inducer rifampicin might cause moderate exposure reduction.	RG7388	82-93	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	33-39
34180037-0	2021	Phase I study of daily and weekly regimens of the orally administered MDM2 antagonist idasanutlin in patients with advanced tumors.	RG7388	86-97	MDM2 proto-oncogene	Homo sapiens	70-74
34180037-1	2021	Aim The oral MDM2 antagonist idasanutlin inhibits the p53-MDM2 interaction, enabling p53 activation, tumor growth inhibition, and increased survival in xenograft models.	RG7388	29-40	MDM2 proto-oncogene	Homo sapiens	13-17
34180037-1	2021	Aim The oral MDM2 antagonist idasanutlin inhibits the p53-MDM2 interaction, enabling p53 activation, tumor growth inhibition, and increased survival in xenograft models.	RG7388	29-40	tumor protein p53	Homo sapiens	54-57
34180037-1	2021	Aim The oral MDM2 antagonist idasanutlin inhibits the p53-MDM2 interaction, enabling p53 activation, tumor growth inhibition, and increased survival in xenograft models.	RG7388	29-40	MDM2 proto-oncogene	Homo sapiens	58-62
34180037-1	2021	Aim The oral MDM2 antagonist idasanutlin inhibits the p53-MDM2 interaction, enabling p53 activation, tumor growth inhibition, and increased survival in xenograft models.	RG7388	29-40	tumor protein p53	Homo sapiens	85-88
34180037-14	2021	Conclusions Idasanutlin demonstrated dose- and schedule-dependent p53 activation with durable disease stabilization in some patients.	RG7388	12-23	tumor protein p53	Homo sapiens	66-69
34523337-0	2021	Fluorine-18 Labeling of the MDM2 Inhibitor RG7388 for PET Imaging: Chemistry and Preliminary Evaluation.	RG7388	43-49	transformed mouse 3T3 cell double minute 2	Mus musculus	28-32
34732238-6	2021	In this study, we performed a comprehensive validation of MDM2 inhibitor RG7388 in patient-derived DIPG cell lines established from both TP53 wild-type/PPM1D-mutant and TP53 mutant/PPM1D wild-type tumors, as well in TP53 knockout isogenic DIPG cell line models.	RG7388	73-79	MDM2 proto-oncogene	Homo sapiens	58-62
34732238-7	2021	RG7388 selectively inhibited the proliferation of the TP53 wild-type/PPM1D mutant DIPG cell lines in a dose- and time-dependent manner.	RG7388	0-6	tumor protein p53	Homo sapiens	54-58
34732238-7	2021	RG7388 selectively inhibited the proliferation of the TP53 wild-type/PPM1D mutant DIPG cell lines in a dose- and time-dependent manner.	RG7388	0-6	protein phosphatase, Mg2+/Mn2+ dependent 1D	Homo sapiens	69-74
34732238-9	2021	RNA-Seq data showed that differential gene expression induced by RG7388 treatment was enriched in the p53 pathways.	RG7388	65-71	tumor protein p53	Homo sapiens	102-105
34732238-10	2021	RG7388 reactivated the p53 pathway and induced apoptosis as well as G1 arrest.	RG7388	0-6	tumor protein p53	Homo sapiens	23-26
34732238-12	2021	Hence, this study demonstrates the pre-clinical efficacy potential of RG7388 in the TP53 wild-type/PPM1D mutant DIPG subgroup and may provide critical insight on the design of future clinical trials applying this drug in DIPG patients.	RG7388	70-76	protein phosphatase, Mg2+/Mn2+ dependent 1D	Homo sapiens	99-104
34523337-1	2021	RG7388 (Idasanutlin) is a potent inhibitor of oncoprotein murine double minute 2 (MDM2).	RG7388	0-6	transformed mouse 3T3 cell double minute 2	Mus musculus	58-80
34523337-1	2021	RG7388 (Idasanutlin) is a potent inhibitor of oncoprotein murine double minute 2 (MDM2).	RG7388	0-6	transformed mouse 3T3 cell double minute 2	Mus musculus	82-86
34523337-1	2021	RG7388 (Idasanutlin) is a potent inhibitor of oncoprotein murine double minute 2 (MDM2).	RG7388	8-19	transformed mouse 3T3 cell double minute 2	Mus musculus	58-80
34523337-1	2021	RG7388 (Idasanutlin) is a potent inhibitor of oncoprotein murine double minute 2 (MDM2).	RG7388	8-19	transformed mouse 3T3 cell double minute 2	Mus musculus	82-86
34523337-2	2021	Herein we investigated the feasibility of developing 18F-labeled RG7388 as a radiotracer for imaging MDM2 expression in tumors with positron emission tomography (PET).	RG7388	65-71	transformed mouse 3T3 cell double minute 2	Mus musculus	101-105
34523337-3	2021	Two fluorinated analogues of RG7388, 6 and 7, were synthesized by attaching a fluoronicotinyl moiety to RG7388 via a polyethylene glycol (PEG3) or a propyl linker.	RG7388	29-35	paternally expressed 3	Mus musculus	138-142
34523337-3	2021	Two fluorinated analogues of RG7388, 6 and 7, were synthesized by attaching a fluoronicotinyl moiety to RG7388 via a polyethylene glycol (PEG3) or a propyl linker.	RG7388	104-110	paternally expressed 3	Mus musculus	138-142
34523337-14	2021	Our results suggest that RG7388 is a promising molecular scaffold for 18F-labeled probe development for MDM2.	RG7388	25-31	transformed mouse 3T3 cell double minute 2	Mus musculus	104-108
35179215-6	2022	Using cell viability, colony formation and methylcellulose assays it was found that genetic MDM2 inhibition with short hairpin RNA or chemical MDM2 inhibition with small molecule inhibitors, Nutlin3 and idasanutlin (RG7388) decreased the growth of ATRT cell lines.	RG7388	203-214	MDM2 proto-oncogene	Homo sapiens	92-96
34100216-3	2021	The objective of this research was to apply the concepts of nanotechnology to develop a multi-drug therapy, TMZ and idasanutlin (RG7388, a potent mouse double minute 2 (MDM2) antagonist), loaded in functionalized nanoparticles (NPs) that target the GBM CSC subpopulation, reduce the cell viability and provide possibility of in vivo preclinical imaging.	RG7388	116-127	transformed mouse 3T3 cell double minute 2	Mus musculus	169-173
34100216-3	2021	The objective of this research was to apply the concepts of nanotechnology to develop a multi-drug therapy, TMZ and idasanutlin (RG7388, a potent mouse double minute 2 (MDM2) antagonist), loaded in functionalized nanoparticles (NPs) that target the GBM CSC subpopulation, reduce the cell viability and provide possibility of in vivo preclinical imaging.	RG7388	129-135	transformed mouse 3T3 cell double minute 2	Mus musculus	169-173
35420431-3	2022	In three MDM4-overexpressing cancer cell lines harboring wild-type p53, 31 shows improved cell growth inhibition activities compared to RG7388, an MDM2-selective inhibitor in late-stage clinical trials.	RG7388	136-142	MDM4 regulator of p53	Homo sapiens	9-13
35420431-3	2022	In three MDM4-overexpressing cancer cell lines harboring wild-type p53, 31 shows improved cell growth inhibition activities compared to RG7388, an MDM2-selective inhibitor in late-stage clinical trials.	RG7388	136-142	tumor protein p53	Homo sapiens	67-70
35420431-3	2022	In three MDM4-overexpressing cancer cell lines harboring wild-type p53, 31 shows improved cell growth inhibition activities compared to RG7388, an MDM2-selective inhibitor in late-stage clinical trials.	RG7388	136-142	MDM2 proto-oncogene	Homo sapiens	147-151
35413116-1	2022	The phase III MIRROS trial (NCT02545283) evaluated the efficacy and safety of the small-molecule MDM2 antagonist idasanutlin plus cytarabine in patients with relapsed/refractory acute myeloid leukemia (R/R AML).	RG7388	113-124	MDM2 proto-oncogene	Homo sapiens	97-101
35440992-6	2022	Notably, the synthetic utility of a reversed 1,3-DC/(H/D-Ex) protocol has been demonstrated by catalytic asymmetric synthesis of deuterium-labelled MDM2 antagonist idasanutlin (RG7388) with high deuterium incorporation.	RG7388	164-175	MDM2 proto-oncogene	Homo sapiens	148-152
35440992-6	2022	Notably, the synthetic utility of a reversed 1,3-DC/(H/D-Ex) protocol has been demonstrated by catalytic asymmetric synthesis of deuterium-labelled MDM2 antagonist idasanutlin (RG7388) with high deuterium incorporation.	RG7388	177-183	MDM2 proto-oncogene	Homo sapiens	148-152
35179215-6	2022	Using cell viability, colony formation and methylcellulose assays it was found that genetic MDM2 inhibition with short hairpin RNA or chemical MDM2 inhibition with small molecule inhibitors, Nutlin3 and idasanutlin (RG7388) decreased the growth of ATRT cell lines.	RG7388	216-222	MDM2 proto-oncogene	Homo sapiens	92-96
35179215-6	2022	Using cell viability, colony formation and methylcellulose assays it was found that genetic MDM2 inhibition with short hairpin RNA or chemical MDM2 inhibition with small molecule inhibitors, Nutlin3 and idasanutlin (RG7388) decreased the growth of ATRT cell lines.	RG7388	216-222	MDM2 proto-oncogene	Homo sapiens	143-147
35179215-9	2022	Immunohistochemistry revealed an increased number of caspase-3-positive cells in the idasanutlin treatment group, confirming the induction of apoptosis in vivo.	RG7388	85-96	caspase 3	Homo sapiens	53-62
35179215-6	2022	Using cell viability, colony formation and methylcellulose assays it was found that genetic MDM2 inhibition with short hairpin RNA or chemical MDM2 inhibition with small molecule inhibitors, Nutlin3 and idasanutlin (RG7388) decreased the growth of ATRT cell lines.	RG7388	203-214	MDM2 proto-oncogene	Homo sapiens	143-147
33190064-6	2021	In our panel of ten cell lines with a spectrum of aberrations in the p53 and pRb pathway, idasanutlin and abemaciclib were the most potent MDM2 and CDK4/6 inhibitors, respectively.	RG7388	90-101	tumor protein p53	Homo sapiens	69-72
34861697-2	2022	Here we report that MDM2 inhibitors (MDM2i) navtemadlin and idasanutlin have potent in vivo activity in EBV+ B-cell lymphoma established in immunocompromised mice.	RG7388	60-71	MDM2 proto-oncogene	Homo sapiens	20-24
33850004-7	2021	Overall, high-throughput drug screening identified the MDM2 inhibitor idasanutlin as a promising resensitizing agent for venetoclax-resistant neuroblastoma cell lines.	RG7388	70-81	MDM2 proto-oncogene	Homo sapiens	55-59
33850004-8	2021	Idasanutlin treatment induced BAX-mediated apoptosis in venetoclax-resistant neuroblastoma cells in the presence of venetoclax, while it caused p21-mediated growth arrest in control cells.	RG7388	0-11	BCL2 associated X, apoptosis regulator	Homo sapiens	30-33
33850004-8	2021	Idasanutlin treatment induced BAX-mediated apoptosis in venetoclax-resistant neuroblastoma cells in the presence of venetoclax, while it caused p21-mediated growth arrest in control cells.	RG7388	0-11	H3 histone pseudogene 16	Homo sapiens	144-147
33850004-11	2021	This study demonstrates that idasanutlin can overcome resistance to the BCL-2 inhibitor venetoclax in preclinical neuroblastoma model systems, which supports clinical development of a treatment strategy combining the two therapies.	RG7388	29-40	BCL2 apoptosis regulator	Homo sapiens	72-77
33668835-4	2021	In this study, we used the MDM2 antagonist idasanutlin (RG7388) to investigate the responses of primary human macrophages to pharmacological p53 activation.	RG7388	43-54	MDM2 proto-oncogene	Homo sapiens	27-31
33668835-4	2021	In this study, we used the MDM2 antagonist idasanutlin (RG7388) to investigate the responses of primary human macrophages to pharmacological p53 activation.	RG7388	56-62	MDM2 proto-oncogene	Homo sapiens	27-31
33668835-5	2021	Idasanutlin induced a robust p53-dependent transcriptional signature in macrophages, including several pro-apoptotic genes.	RG7388	0-11	tumor protein p53	Homo sapiens	29-32
33668835-7	2021	In fully differentiated macrophages, idasanutlin did not affect pro-inflammatory gene expression induced by toll-like receptor 4 (TLR4), TLR3, and TLR7/8 agonists, but inhibited interleukin-4-induced macrophage polarization.	RG7388	37-48	interleukin 4	Homo sapiens	178-191
33668835-8	2021	However, when present during monocyte to macrophage differentiation, idasanutlin attenuated inflammatory responses towards activation of TLR4 and TLR7/8 by low doses of lipopolysaccharide or resiquimod (R848).	RG7388	69-80	toll like receptor 4	Homo sapiens	137-141
33668835-8	2021	However, when present during monocyte to macrophage differentiation, idasanutlin attenuated inflammatory responses towards activation of TLR4 and TLR7/8 by low doses of lipopolysaccharide or resiquimod (R848).	RG7388	69-80	toll like receptor 7	Homo sapiens	146-152
33668835-9	2021	This was accompanied by a reduced expression of CD14, TLR7, and TLR8 in macrophages differentiated in the presence of idasanutlin.	RG7388	118-129	CD14 molecule	Homo sapiens	48-52
33668835-9	2021	This was accompanied by a reduced expression of CD14, TLR7, and TLR8 in macrophages differentiated in the presence of idasanutlin.	RG7388	118-129	toll like receptor 7	Homo sapiens	54-58
33668835-9	2021	This was accompanied by a reduced expression of CD14, TLR7, and TLR8 in macrophages differentiated in the presence of idasanutlin.	RG7388	118-129	toll like receptor 8	Homo sapiens	64-68
33190064-6	2021	In our panel of ten cell lines with a spectrum of aberrations in the p53 and pRb pathway, idasanutlin and abemaciclib were the most potent MDM2 and CDK4/6 inhibitors, respectively.	RG7388	90-101	RB transcriptional corepressor 1	Homo sapiens	77-80
33190064-6	2021	In our panel of ten cell lines with a spectrum of aberrations in the p53 and pRb pathway, idasanutlin and abemaciclib were the most potent MDM2 and CDK4/6 inhibitors, respectively.	RG7388	90-101	MDM2 proto-oncogene	Homo sapiens	139-143
33190064-6	2021	In our panel of ten cell lines with a spectrum of aberrations in the p53 and pRb pathway, idasanutlin and abemaciclib were the most potent MDM2 and CDK4/6 inhibitors, respectively.	RG7388	90-101	cyclin dependent kinase 4	Homo sapiens	148-154
32806555-6	2020	MDM2 antagonist (RG7388)-resistant IB115 [P4] cells and p53-silenced DDLPS cells were also established to understand the importance of functional p53.	RG7388	17-23	transformed mouse 3T3 cell double minute 2	Mus musculus	0-4
33051060-10	2020	Additionally, in vitro and in vivo results showed that MET and/or RG7388 inhibited the phosphoinositide 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway and their combination had a stronger effect.	RG7388	66-72	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Homo sapiens	87-112
33051060-10	2020	Additionally, in vitro and in vivo results showed that MET and/or RG7388 inhibited the phosphoinositide 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway and their combination had a stronger effect.	RG7388	66-72	AKT serine/threonine kinase 1	Homo sapiens	120-123
33051060-10	2020	Additionally, in vitro and in vivo results showed that MET and/or RG7388 inhibited the phosphoinositide 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway and their combination had a stronger effect.	RG7388	66-72	mechanistic target of rapamycin kinase	Homo sapiens	124-153
33051060-10	2020	Additionally, in vitro and in vivo results showed that MET and/or RG7388 inhibited the phosphoinositide 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway and their combination had a stronger effect.	RG7388	66-72	mechanistic target of rapamycin kinase	Homo sapiens	155-159
33051060-11	2020	Our findings suggest that the combination of MET and RG7388 enhances growth inhibition and apoptosis induction of ovarian cancer cells through the PI3K/AKT/mTOR pathway and accumulation of intracellular ROS.	RG7388	53-59	AKT serine/threonine kinase 1	Homo sapiens	152-155
33051060-11	2020	Our findings suggest that the combination of MET and RG7388 enhances growth inhibition and apoptosis induction of ovarian cancer cells through the PI3K/AKT/mTOR pathway and accumulation of intracellular ROS.	RG7388	53-59	mechanistic target of rapamycin kinase	Homo sapiens	156-160
33216890-0	2020	Transient expansion of TP53 mutated clones in polycythemia vera patients treated with idasanutlin.	RG7388	86-97	tumor protein p53	Homo sapiens	23-27
33216890-4	2020	Here, we present data indicating that idasanutlin therapy is associated with expansion of TP53 mutant subclones.	RG7388	38-49	tumor protein p53	Homo sapiens	90-94
33216890-7	2020	Follow-up samples were obtained from 4 of 5 patients in this cohort, and we observed that after cessation of idasanutlin, the variant allele frequency (VAF) of 8 of 9 TP53 mutations decreased.	RG7388	109-120	tumor protein p53	Homo sapiens	167-171
33216890-9	2020	These data suggest that idasanutlin treatment may promote transient TP53 mutant clonal expansion.	RG7388	24-35	tumor protein p53	Homo sapiens	68-72
32827690-4	2020	In this study, we are reporting the differential mechanism of cell death induced by the two small-molecule inhibitors, named RG-7388 and Nutlin-3, that are specific for MDM2 in SJSA-1 Osteosarcoma cells (OS).	RG7388	125-132	MDM2 proto-oncogene	Homo sapiens	169-173
32827690-5	2020	Mechanistically, RG-7388 was able to enhance the phosphorylation of Mcl-1, which appears to significantly enhance its degradation, thereby relieving the pro-apoptotic protein Bak to execute the apoptosis mechanism.	RG7388	17-24	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	68-73
32827690-5	2020	Mechanistically, RG-7388 was able to enhance the phosphorylation of Mcl-1, which appears to significantly enhance its degradation, thereby relieving the pro-apoptotic protein Bak to execute the apoptosis mechanism.	RG7388	17-24	BCL2 antagonist/killer 1	Homo sapiens	175-178
32827690-7	2020	Additionally, we noted that CHIR-99021 (GSK-3beta inhibitor) blocked the cytotoxicity exerted by RG-7388 on SJSA-1 cells by decreasing Bak levels.	RG7388	97-104	glycogen synthase kinase 3 alpha	Homo sapiens	40-49
32827690-7	2020	Additionally, we noted that CHIR-99021 (GSK-3beta inhibitor) blocked the cytotoxicity exerted by RG-7388 on SJSA-1 cells by decreasing Bak levels.	RG7388	97-104	BCL2 antagonist/killer 1	Homo sapiens	135-138
32827690-12	2020	This study further opens new avenues for the use of RG-7388 in treating osteosarcomas that often becomes resistant to chemotherapy due to Bcl-2 overexpression.	RG7388	52-59	BCL2 apoptosis regulator	Homo sapiens	138-143
33051060-0	2020	Combination of metformin and RG7388 enhances inhibition of growth and induction of apoptosis of ovarian cancer cells through the PI3K/AKT/mTOR pathway.	RG7388	29-35	AKT serine/threonine kinase 1	Homo sapiens	134-137
33051060-0	2020	Combination of metformin and RG7388 enhances inhibition of growth and induction of apoptosis of ovarian cancer cells through the PI3K/AKT/mTOR pathway.	RG7388	29-35	mechanistic target of rapamycin kinase	Homo sapiens	138-142
33092134-6	2020	Combining erdafitinib with the MDM2 antagonist RG7388 exerted a synergistic effect on viability, apoptosis, and clonogenicity in one WDLPS and two DDLPS cell lines.	RG7388	47-53	MDM2 proto-oncogene	Homo sapiens	31-35
32741700-6	2022	Currently, multiple p53-MDM2/MDM4 antagonists are undergoing clinical trials, the most advanced being idasanutlin which is currently undergoing testing in a phase III clinical trial in patients with relapsed or refractory acute myeloid leukemia.	RG7388	102-113	tumor protein p53	Homo sapiens	20-23
32020437-2	2020	RO6839921 is an inactive pegylated prodrug of the oral MDM2 antagonist idasanutlin (active principle [AP]) that allows for IV administration.	RG7388	71-82	MDM2 proto-oncogene	Homo sapiens	55-59
31734832-0	2020	A phase 1 study of the MDM2 antagonist RO6839921, a pegylated prodrug of idasanutlin, in patients with advanced solid tumors.	RG7388	73-84	MDM2 proto-oncogene	Homo sapiens	23-27
31734832-2	2020	RO6839921 is an inactive pegylated prodrug of idasanutlin, an MDM2 antagonist, developed for intravenous administration.	RG7388	46-57	MDM2 proto-oncogene	Homo sapiens	62-66
32741700-6	2022	Currently, multiple p53-MDM2/MDM4 antagonists are undergoing clinical trials, the most advanced being idasanutlin which is currently undergoing testing in a phase III clinical trial in patients with relapsed or refractory acute myeloid leukemia.	RG7388	102-113	MDM2 proto-oncogene	Homo sapiens	24-28
32741700-6	2022	Currently, multiple p53-MDM2/MDM4 antagonists are undergoing clinical trials, the most advanced being idasanutlin which is currently undergoing testing in a phase III clinical trial in patients with relapsed or refractory acute myeloid leukemia.	RG7388	102-113	MDM4 regulator of p53	Homo sapiens	29-33
32629830-8	2020	When combined with imidazoline MDM2 inhibitors (Nutlin-3a and Idasanutlin/RG-7388), synergism was observed in cancer cell growth inhibition.	RG7388	62-73	transformed mouse 3T3 cell double minute 2	Mus musculus	31-35
32629830-8	2020	When combined with imidazoline MDM2 inhibitors (Nutlin-3a and Idasanutlin/RG-7388), synergism was observed in cancer cell growth inhibition.	RG7388	74-81	transformed mouse 3T3 cell double minute 2	Mus musculus	31-35
31004033-5	2019	In this study we tested the second-generation MDM2 inhibitor, RG7388, in patient-derived CLL cells and normal cells, examining its effect on the induction of p53-transcriptional targets.	RG7388	62-68	MDM2 proto-oncogene	Homo sapiens	46-50
32167393-2	2020	Idasanutlin is a small-molecule inhibitor of MDM2, a negative regulator of tumor suppressor p53.	RG7388	0-11	MDM2 proto-oncogene	Homo sapiens	45-49
32167393-2	2020	Idasanutlin is a small-molecule inhibitor of MDM2, a negative regulator of tumor suppressor p53.	RG7388	0-11	tumor protein p53	Homo sapiens	92-95
32167393-3	2020	By preventing the p53-MDM2 interaction, idasanutlin allows for p53 activation, particularly in patients with TP53 wild-type (WT) status.	RG7388	40-51	tumor protein p53	Homo sapiens	18-21
32167393-3	2020	By preventing the p53-MDM2 interaction, idasanutlin allows for p53 activation, particularly in patients with TP53 wild-type (WT) status.	RG7388	40-51	MDM2 proto-oncogene	Homo sapiens	22-26
32167393-3	2020	By preventing the p53-MDM2 interaction, idasanutlin allows for p53 activation, particularly in patients with TP53 wild-type (WT) status.	RG7388	40-51	tumor protein p53	Homo sapiens	63-66
32167393-3	2020	By preventing the p53-MDM2 interaction, idasanutlin allows for p53 activation, particularly in patients with TP53 wild-type (WT) status.	RG7388	40-51	tumor protein p53	Homo sapiens	109-113
31568878-0	2019	Co-delivery of p53 and MDM2 inhibitor RG7388 using a hydroxyl terminal PAMAM dendrimer derivative for synergistic cancer therapy.	RG7388	38-44	MDM2 proto-oncogene	Homo sapiens	23-27
31568878-3	2019	PAMSPF was able to condense DNA and encapsulate RG7388 to form spherical nanoparticles (PAMSPF/p53/RG) with particle sizes of around 200 nm, and remain stable in the presence of heparin and nuclease.	RG7388	48-54	tumor protein p53	Homo sapiens	95-98
31568878-4	2019	The drug loading capacity and encapsulation efficiency of RG7388 in PAMSPF/p53/RG were 0.5% and 92.5%, respectively.	RG7388	58-64	tumor protein p53	Homo sapiens	75-78
31568878-8	2019	And the biological activities described above of PAMSPF/p53/RG were significantly higher than those of PAMSPF/53 and PAMSPF/RG, exhibiting the synergistic actions of p53 plasmid and RG7388.	RG7388	182-188	tumor protein p53	Homo sapiens	56-59
31568878-11	2019	Collectively, PAMSPF/p53/RG is an excellent system for gene and drug co-delivery, and the combined treatment of p53 plasmid and RG7388 possesses a synergistic antitumor activity both in vitro and in vivo.	RG7388	128-134	tumor protein p53	Homo sapiens	21-24
31004033-5	2019	In this study we tested the second-generation MDM2 inhibitor, RG7388, in patient-derived CLL cells and normal cells, examining its effect on the induction of p53-transcriptional targets.	RG7388	62-68	tumor protein p53	Homo sapiens	158-161
31004033-6	2019	RG7388 potently decreased viability in p53-functional CLL cells, whereas p53-non-functional samples were more resistant to the drug.	RG7388	0-6	tumor protein p53	Homo sapiens	39-42
31004033-7	2019	RG7388 induced a pro-apoptotic gene expression signature with upregulation of p53-target genes involved in the intrinsic (PUMA, BAX) and extrinsic (TNFRSF10B, FAS) pathways of apoptosis, as well as MDM2 Only a slight induction of CDKN1A was observed and upregulation of pro-apoptotic genes dominated, indicating that CLL cells are primed for p53-dependent apoptosis.	RG7388	0-6	tumor protein p53	Homo sapiens	78-81
31004033-7	2019	RG7388 induced a pro-apoptotic gene expression signature with upregulation of p53-target genes involved in the intrinsic (PUMA, BAX) and extrinsic (TNFRSF10B, FAS) pathways of apoptosis, as well as MDM2 Only a slight induction of CDKN1A was observed and upregulation of pro-apoptotic genes dominated, indicating that CLL cells are primed for p53-dependent apoptosis.	RG7388	0-6	BCL2 binding component 3	Homo sapiens	122-126
31004033-7	2019	RG7388 induced a pro-apoptotic gene expression signature with upregulation of p53-target genes involved in the intrinsic (PUMA, BAX) and extrinsic (TNFRSF10B, FAS) pathways of apoptosis, as well as MDM2 Only a slight induction of CDKN1A was observed and upregulation of pro-apoptotic genes dominated, indicating that CLL cells are primed for p53-dependent apoptosis.	RG7388	0-6	BCL2 associated X, apoptosis regulator	Homo sapiens	128-131
31004033-7	2019	RG7388 induced a pro-apoptotic gene expression signature with upregulation of p53-target genes involved in the intrinsic (PUMA, BAX) and extrinsic (TNFRSF10B, FAS) pathways of apoptosis, as well as MDM2 Only a slight induction of CDKN1A was observed and upregulation of pro-apoptotic genes dominated, indicating that CLL cells are primed for p53-dependent apoptosis.	RG7388	0-6	TNF receptor superfamily member 10b	Homo sapiens	148-157
31004033-7	2019	RG7388 induced a pro-apoptotic gene expression signature with upregulation of p53-target genes involved in the intrinsic (PUMA, BAX) and extrinsic (TNFRSF10B, FAS) pathways of apoptosis, as well as MDM2 Only a slight induction of CDKN1A was observed and upregulation of pro-apoptotic genes dominated, indicating that CLL cells are primed for p53-dependent apoptosis.	RG7388	0-6	MDM2 proto-oncogene	Homo sapiens	198-202
31004033-7	2019	RG7388 induced a pro-apoptotic gene expression signature with upregulation of p53-target genes involved in the intrinsic (PUMA, BAX) and extrinsic (TNFRSF10B, FAS) pathways of apoptosis, as well as MDM2 Only a slight induction of CDKN1A was observed and upregulation of pro-apoptotic genes dominated, indicating that CLL cells are primed for p53-dependent apoptosis.	RG7388	0-6	cyclin dependent kinase inhibitor 1A	Homo sapiens	230-236
31004033-7	2019	RG7388 induced a pro-apoptotic gene expression signature with upregulation of p53-target genes involved in the intrinsic (PUMA, BAX) and extrinsic (TNFRSF10B, FAS) pathways of apoptosis, as well as MDM2 Only a slight induction of CDKN1A was observed and upregulation of pro-apoptotic genes dominated, indicating that CLL cells are primed for p53-dependent apoptosis.	RG7388	0-6	tumor protein p53	Homo sapiens	342-345
31004033-8	2019	Consequently, RG7388 led to a concentration-dependent increase in caspase-3/7 activity and cleaved poly (ADP-ribose) polymerase.	RG7388	14-20	caspase 3	Homo sapiens	66-77
31004033-8	2019	Consequently, RG7388 led to a concentration-dependent increase in caspase-3/7 activity and cleaved poly (ADP-ribose) polymerase.	RG7388	14-20	poly(ADP-ribose) polymerase 1	Homo sapiens	99-127
30274984-0	2019	Targeting Resistance against the MDM2 Inhibitor RG7388 in Glioblastoma Cells by the MEK Inhibitor Trametinib.	RG7388	48-54	transformed mouse 3T3 cell double minute 2	Mus musculus	33-37
31167802-5	2019	Therefore, we performed an investigator-initiated phase 1 trial of the oral MDM2 antagonist idasanutlin (RG7388; Roche) in patients with high-risk PV/ET for whom at least 1 prior therapy had failed.	RG7388	92-103	MDM2 proto-oncogene	Homo sapiens	76-80
31062077-1	2019	PURPOSE: Idasanutlin, a selective small-molecule MDM2 antagonist in phase 3 testing for refractory/relapsed AML, is a non-genotoxic p53 activator with oral administration.	RG7388	9-20	MDM2 proto-oncogene	Homo sapiens	49-53
31062077-1	2019	PURPOSE: Idasanutlin, a selective small-molecule MDM2 antagonist in phase 3 testing for refractory/relapsed AML, is a non-genotoxic p53 activator with oral administration.	RG7388	9-20	tumor protein p53	Homo sapiens	132-135
30511219-1	2019	PURPOSE: Idasanutlin is a selective small-molecule MDM2 antagonist.	RG7388	9-20	MDM2 proto-oncogene	Homo sapiens	51-55
30511219-5	2019	Thus, the aim of this analysis is to investigate if UGT polymorphism is associated with idasanutlin pharmacokinetics.	RG7388	88-99	UDP glucuronosyltransferase family 1 member A complex locus	Homo sapiens	52-55
31689961-10	2019	A clinical phase III trial using MDM2/X inhibitors, idasanutlin (RG7388) combined with cytarabine, is being performed involving relapse/refractory acute myeloid leukemia patients.	RG7388	65-71	MDM2 proto-oncogene	Homo sapiens	33-37
30536898-3	2019	This is the first study to evaluate the in vivo efficacy of the intravenous idasanutlin prodrug, RO6839921 (RG7775), both alone and in combination with temozolomide in TP53 wt orthotopic neuroblastoma models.	RG7388	76-87	tumor protein p53	Homo sapiens	168-172
30536898-4	2019	Detection of active idasanutlin using liquid chromatography-mass spectrometry and p53 pathway activation by ELISA assays and Western analysis showed peak plasma levels 1 h post-treatment with maximal p53 pathway activation 3-6 h post-treatment.	RG7388	20-31	tumor protein p53	Homo sapiens	200-203
30755442-4	2019	Using two compounds currently in clinical development, idasanutlin (MDM2-specific) and ATSP-7041 (MDM2/4-dual), we show that MRT cells were more sensitive than other p53 wild-type cancer cell lines to inhibition of MDM2 alone as well as dual inhibition of MDM2/4.	RG7388	55-66	transformed mouse 3T3 cell double minute 2	Mus musculus	68-72
31289443-0	2019	MDM2 antagonists as a novel treatment option for acute myeloid leukemia: perspectives on the therapeutic potential of idasanutlin (RG7388).	RG7388	118-129	transformed mouse 3T3 cell double minute 2	Mus musculus	0-4
30647052-1	2019	The BCL2 inhibitor venetoclax plus the MDM2 inhibitor idasanutlin may be effective in treating relapsed/refractory acute myeloid leukemia.	RG7388	54-65	MDM2 proto-oncogene	Homo sapiens	39-43
30700046-3	2019	The small molecule RG7388 (idasanutlin, R05503781) is a newly developed inhibitor that is specific for an oncogene-derived protein called MDM2, which is also in clinical trials for the treatment of various types of cancers.	RG7388	27-38	MDM2 proto-oncogene	Homo sapiens	138-142
29392451-1	2018	PURPOSE: Idasanutlin, a selective small-molecule MDM2 antagonist in phase 3 testing for refractory/relapsed AML, is a non-genotoxic oral p53 activator.	RG7388	9-20	MDM2 proto-oncogene	Homo sapiens	49-53
31311404-0	2019	MDM2 inhibitor RG7388 potently inhibits tumors by activating p53 pathway in nasopharyngeal carcinoma.	RG7388	15-21	transformed mouse 3T3 cell double minute 2	Mus musculus	0-4
31311404-0	2019	MDM2 inhibitor RG7388 potently inhibits tumors by activating p53 pathway in nasopharyngeal carcinoma.	RG7388	15-21	transformation related protein 53, pseudogene	Mus musculus	61-64
31311404-5	2019	The latest generation MDM2 inhibitor, RG7388, shows increased potency and improved bioavailability compared to previous treatments.	RG7388	38-44	transformed mouse 3T3 cell double minute 2	Mus musculus	22-26
30543590-8	2018	Early-phase clinical trials have also suggested that MDM2 inhibitors such as idasanutlin and histone deacetylase inhibitors should continue in their development.	RG7388	77-88	MDM2 proto-oncogene	Homo sapiens	53-57
30352966-0	2018	Prolonged Idasanutlin (RG7388) Treatment Leads to the Generation of p53-Mutated Cells.	RG7388	10-21	tumor protein p53	Homo sapiens	68-71
30352966-6	2018	In the present study, we show that secondary resistance occurs also after treatment of p53wt cells with idasanutlin (RG7388, RO5503781), which is the only MDM2 antagonist that has passed phase II and entered phase III clinical trials, so far.	RG7388	104-115	tumor protein p53	Homo sapiens	87-90
30352966-6	2018	In the present study, we show that secondary resistance occurs also after treatment of p53wt cells with idasanutlin (RG7388, RO5503781), which is the only MDM2 antagonist that has passed phase II and entered phase III clinical trials, so far.	RG7388	104-115	MDM2 proto-oncogene	Homo sapiens	155-159
30352966-7	2018	Idasanutlin strongly activates p53, as evidenced by the induction of p21 expression and potent cell cycle arrest in all the three cell lines tested, i.e., MCF-7, U-2 OS, and SJSA-1.	RG7388	0-11	tumor protein p53	Homo sapiens	31-34
30352966-7	2018	Idasanutlin strongly activates p53, as evidenced by the induction of p21 expression and potent cell cycle arrest in all the three cell lines tested, i.e., MCF-7, U-2 OS, and SJSA-1.	RG7388	0-11	H3 histone pseudogene 16	Homo sapiens	69-72
30352966-12	2018	Thus, although idasanutlin presents much improved activities compared to its precursor, it displays the similar weaknesses, which are limited elimination of cancer cells and the generation of p53-mutated drug-resistant subpopulations.	RG7388	15-26	tumor protein p53	Homo sapiens	192-195
30158012-1	2018	A concise asymmetric synthesis has been developed to prepare idasanutlin, a small molecule MDM2 antagonist.	RG7388	61-72	MDM2 proto-oncogene	Homo sapiens	91-95
29857559-0	2018	The Cellular p53 Inhibitor MDM2 and the Growth Factor Receptor FLT3 as Biomarkers for Treatment Responses to the MDM2-Inhibitor Idasanutlin and the MEK1 Inhibitor Cobimetinib in Acute Myeloid Leukemia.	RG7388	128-139	transformation related protein 53	Mus musculus	13-16
29857559-0	2018	The Cellular p53 Inhibitor MDM2 and the Growth Factor Receptor FLT3 as Biomarkers for Treatment Responses to the MDM2-Inhibitor Idasanutlin and the MEK1 Inhibitor Cobimetinib in Acute Myeloid Leukemia.	RG7388	128-139	transformed mouse 3T3 cell double minute 2	Mus musculus	27-31
29857559-0	2018	The Cellular p53 Inhibitor MDM2 and the Growth Factor Receptor FLT3 as Biomarkers for Treatment Responses to the MDM2-Inhibitor Idasanutlin and the MEK1 Inhibitor Cobimetinib in Acute Myeloid Leukemia.	RG7388	128-139	FMS-like tyrosine kinase 3	Mus musculus	63-67
29857559-0	2018	The Cellular p53 Inhibitor MDM2 and the Growth Factor Receptor FLT3 as Biomarkers for Treatment Responses to the MDM2-Inhibitor Idasanutlin and the MEK1 Inhibitor Cobimetinib in Acute Myeloid Leukemia.	RG7388	128-139	transformed mouse 3T3 cell double minute 2	Mus musculus	113-117
29857559-5	2018	Here we assessed the MDM2 antagonist idasanutlin and the MEK1 inhibitor cobimetinib as single agents and in combination in a variety of AML cell lines and primary AML blast cells for their ability to induce apoptosis and cell death.	RG7388	37-48	transformed mouse 3T3 cell double minute 2	Mus musculus	21-25
29857559-9	2018	Our data indicate that AML cells with normal karyotype (NK) and wild-type status of TP53 with elevated FLT3 and MDM2 expression emerge to be most sensitive to the combined treatment with cobimetinib and idasanutlin.	RG7388	203-214	transformation related protein 53	Mus musculus	84-88
29857559-9	2018	Our data indicate that AML cells with normal karyotype (NK) and wild-type status of TP53 with elevated FLT3 and MDM2 expression emerge to be most sensitive to the combined treatment with cobimetinib and idasanutlin.	RG7388	203-214	FMS-like tyrosine kinase 3	Mus musculus	103-107
29857559-9	2018	Our data indicate that AML cells with normal karyotype (NK) and wild-type status of TP53 with elevated FLT3 and MDM2 expression emerge to be most sensitive to the combined treatment with cobimetinib and idasanutlin.	RG7388	203-214	transformed mouse 3T3 cell double minute 2	Mus musculus	112-116
29857559-10	2018	FLT3 and MDM2 are biomarkers for treatment response to idasanutlin and cobimetinib in AML.	RG7388	55-66	FMS-like tyrosine kinase 3	Mus musculus	0-4
29857559-10	2018	FLT3 and MDM2 are biomarkers for treatment response to idasanutlin and cobimetinib in AML.	RG7388	55-66	transformed mouse 3T3 cell double minute 2	Mus musculus	9-13
29392451-0	2018	Phase 1 summary of plasma concentration-QTc analysis for idasanutlin, an MDM2 antagonist, in patients with advanced solid tumors and AML.	RG7388	57-68	MDM2 proto-oncogene	Homo sapiens	73-77
29392451-1	2018	PURPOSE: Idasanutlin, a selective small-molecule MDM2 antagonist in phase 3 testing for refractory/relapsed AML, is a non-genotoxic oral p53 activator.	RG7388	9-20	tumor protein p53	Homo sapiens	137-140
30158012-0	2018	Efficient Industrial Synthesis of the MDM2 Antagonist Idasanutlin via a Cu(I)-catalyzed [3+2] Asymmetric Cycloaddition.	RG7388	54-65	MDM2 proto-oncogene	Homo sapiens	38-42
29768700-1	2018	Venetoclax (ABT-199) and idasanutlin (RG7388) are efficient anticancer drugs targeting two essential apoptosis markers, Bcl-2 and MDM2, respectively.	RG7388	25-36	BCL2 apoptosis regulator	Homo sapiens	120-125
29768700-1	2018	Venetoclax (ABT-199) and idasanutlin (RG7388) are efficient anticancer drugs targeting two essential apoptosis markers, Bcl-2 and MDM2, respectively.	RG7388	25-36	MDM2 proto-oncogene	Homo sapiens	130-134
29368050-0	2018	Effects of posaconazole (a strong CYP3A4 inhibitor), two new tablet formulations, and food on the pharmacokinetics of idasanutlin, an MDM2 antagonist, in patients with advanced solid tumors.	RG7388	118-129	MDM2 proto-oncogene	Homo sapiens	134-138
29368050-1	2018	PURPOSE: Idasanutlin, a selective small-molecule MDM2 antagonist in phase 3 testing for refractory/relapsed AML, is a non-genotoxic oral p53 activator.	RG7388	9-20	MDM2 proto-oncogene	Homo sapiens	49-53
29368050-1	2018	PURPOSE: Idasanutlin, a selective small-molecule MDM2 antagonist in phase 3 testing for refractory/relapsed AML, is a non-genotoxic oral p53 activator.	RG7388	9-20	tumor protein p53	Homo sapiens	137-140
29368050-6	2018	RESULTS: The administration of posaconazole 400 mg BID x 7 days with idasanutlin 800 mg resulted in a slight decrease (7%) in Cmax and a modest increase (31%) in AUC for idasanutlin, a marked reduction in Cmax (~ 60%) and AUC0 (~ 50%) for M4 metabolite, and a minimal increase (~ 24%) in serum MIC-1 levels.	RG7388	69-80	growth differentiation factor 15	Homo sapiens	294-299
26586447-2	2016	Idasanutlin (RG7388) is a potent p53-MDM2 antagonist currently in clinical development for treatment of cancer.	RG7388	0-11	tumor protein p53	Homo sapiens	33-36
29035366-4	2017	Consequently, targeting of EGFR-driven glucose metabolism in combination with pharmacological stabilization of p53 with the brain-penetrant small molecule idasanutlin resulted in synthetic lethality in orthotopic glioblastoma xenograft models.	RG7388	155-166	tumor protein p53	Homo sapiens	111-114
28915653-4	2017	The venetoclax/idasanutlin combination was consistently found to be highly synergistic in a diverse panel of neuroblastoma cell lines, including cells with high MCL1 expression levels.	RG7388	15-26	myeloid cell leukemia sequence 1	Mus musculus	161-165
28821555-3	2017	Moreover, p53 reactivation via RG7388, a second-generation MDM2 inhibitor, strongly enhances the in vivo antitumor activity of temsirolimus.	RG7388	31-37	tumor protein p53	Homo sapiens	10-13
28821555-3	2017	Moreover, p53 reactivation via RG7388, a second-generation MDM2 inhibitor, strongly enhances the in vivo antitumor activity of temsirolimus.	RG7388	31-37	MDM2 proto-oncogene	Homo sapiens	59-63
26993060-0	2016	Antitumour activity of the glycoengineered type II anti-CD20 antibody obinutuzumab (GA101) in combination with the MDM2-selective antagonist idasanutlin (RG7388).	RG7388	141-152	MDM2 proto-oncogene	Homo sapiens	115-119
26993060-1	2016	OBJECTIVES: To investigate whether the glycoengineered type II anti-CD20 monoclonal antibody obinutuzumab (GA101) combined with the selective MDM2 antagonist idasanutlin (RG7388) offers superior efficacy to monotherapy in treating B-lymphoid malignancies in preclinical models.	RG7388	158-169	MDM2 proto-oncogene	Homo sapiens	142-146
26993060-8	2016	CONCLUSIONS: Obinutuzumab plus idasanutlin enhanced cell death of p53 wild-type tumour cells vs. rituximab plus idasanutlin without affecting obinutuzumab-mediated ADCC or B-cell depletion and showed robust antitumour efficacy in xenograft models, strongly supporting the investigation of this combination in clinical trials.	RG7388	31-42	tumor protein p53	Homo sapiens	66-69
26586447-2	2016	Idasanutlin (RG7388) is a potent p53-MDM2 antagonist currently in clinical development for treatment of cancer.	RG7388	0-11	MDM2 proto-oncogene	Homo sapiens	37-41
26586447-2	2016	Idasanutlin (RG7388) is a potent p53-MDM2 antagonist currently in clinical development for treatment of cancer.	RG7388	13-19	tumor protein p53	Homo sapiens	33-36
26586447-2	2016	Idasanutlin (RG7388) is a potent p53-MDM2 antagonist currently in clinical development for treatment of cancer.	RG7388	13-19	MDM2 proto-oncogene	Homo sapiens	37-41
27353420-0	2016	Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models.	RG7388	52-63	transformed mouse 3T3 cell double minute 2	Mus musculus	36-40
27353420-1	2016	BACKGROUND: Venetoclax, a small molecule BH3 mimetic which inhibits the anti-apoptotic protein Bcl-2, and idasanutlin, a selective MDM2 antagonist, have both shown activity as single-agent treatments in pre-clinical and clinical studies in acute myeloid leukemia (AML).	RG7388	106-117	transformed mouse 3T3 cell double minute 2	Mus musculus	131-135
27353420-2	2016	In this study, we deliver the rationale and molecular basis for the combination of idasanutlin and venetoclax for treatment of p53 wild-type AML.	RG7388	83-94	transformation related protein 53, pseudogene	Mus musculus	127-130
27353420-6	2016	RESULTS: Combination treatment with venetoclax and idasanutlin results in synergistic anti-tumor activity compared with the respective single-agent treatments in vitro, in p53 wild-type AML cell lines, and leads to strongly superior efficacy in vivo, in subcutaneous and orthotopic AML models.	RG7388	51-62	transformation related protein 53, pseudogene	Mus musculus	172-175
27353420-9	2016	As expected, gene expression studies using RNA sequencing showed significant alterations to pathways associated with p53 signaling and cell cycle arrest (CCND1 pathway) in response to idasanutlin treatment.	RG7388	184-195	transformation related protein 53, pseudogene	Mus musculus	117-120
27353420-9	2016	As expected, gene expression studies using RNA sequencing showed significant alterations to pathways associated with p53 signaling and cell cycle arrest (CCND1 pathway) in response to idasanutlin treatment.	RG7388	184-195	cyclin D1	Mus musculus	154-159
27353420-11	2016	Protein expression studies demonstrated that inhibition of the anti-apoptotic protein Mcl-1 contributed to the activity of venetoclax and idasanutlin, with earlier inhibition of Mcl-1 in response to combination treatment contributing to the superior combined activity.	RG7388	138-149	myeloid cell leukemia sequence 1	Mus musculus	86-91
25832557-0	2015	Inhibition of MDM2 by RG7388 confers hypersensitivity to X-radiation in xenograft models of childhood sarcoma.	RG7388	22-28	transformed mouse 3T3 cell double minute 2	Mus musculus	14-18
26998348-0	2015	The MDM2 small-molecule inhibitor RG7388 leads to potent tumor inhibition in p53 wild-type neuroblastoma.	RG7388	34-40	transformed mouse 3T3 cell double minute 2	Mus musculus	4-8
26998348-0	2015	The MDM2 small-molecule inhibitor RG7388 leads to potent tumor inhibition in p53 wild-type neuroblastoma.	RG7388	34-40	transformation related protein 53, pseudogene	Mus musculus	77-80
23808545-4	2013	Here, we report the discovery and characterization of a second generation clinical MDM2 inhibitor, RG7388, with superior potency and selectivity.	RG7388	99-105	MDM2 proto-oncogene	Homo sapiens	83-87
26869629-0	2016	Acute myeloid leukemia patients" clinical response to idasanutlin (RG7388) is associated with pre-treatment MDM2 protein expression in leukemic blasts.	RG7388	54-65	MDM2 proto-oncogene	Homo sapiens	108-112